Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease

Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease

(2010) Cristina Blázquez et al.   BRAIN

Targeting oxidative stress attenuates malonic acid induced Huntington like behavioral and mitochondrial alterations in rats

(2010) Harikesh Kalonia et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Cystamine protects from 3-nitropropionic acid lesioning via induction of nf-e2 related factor 2 mediated transcription

(2010) Marcus J. Calkins et al.   EXPERIMENTAL NEUROLOGY

The endocannabinoid system as a target for the treatment of neuronal damage

(2010) Javier Fernández-Ruiz et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Huntington's disease: progress toward effective disease-modifying treatments and a cure

(2010) C. D. Johnson et al.   HUMAN MOLECULAR GENETICS

Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression

(2010) M. A. Pouladi et al.   HUMAN MOLECULAR GENETICS

Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease

(2010) Chiara Zuccato et al.   PHYSIOLOGICAL REVIEWS

Mitochondria in Huntington's disease

(2009) Maria Damiano et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity

(2009) Javier Palazuelos et al.   BRAIN

Emerging strategies for exploiting cannabinoid receptor agonists as medicines

(2009) Roger G Pertwee   BRITISH JOURNAL OF PHARMACOLOGY

Cannabinoid CB2receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease

(2009) Onintza Sagredo et al.   GLIA

Kaempferol protects against rat striatal degeneration induced by 3-nitropropionic acid

(2009) Ricardo Lagoa et al.   JOURNAL OF NEUROCHEMISTRY

Combination therapy with Coenzyme Q10and creatine produces additive neuroprotective effects in models of Parkinson’s and Huntington’s Diseases

(2009) Lichuan Yang et al.   JOURNAL OF NEUROCHEMISTRY

A pilot study using nabilone for symptomatic treatment in Huntington's disease

(2009) Adrienne Curtis et al.   MOVEMENT DISORDERS

The Endocannabinoid System in Huntingtons Disease

(2008) M. Pazos et al.   CURRENT PHARMACEUTICAL DESIGN

Free Copper, Ferroxidase and SOD1 Activities, Lipid Peroxidation and NO x Content in the CSF. A Different Marker Profile in Four Neurodegenerative Diseases

(2008) Marie-Catherine Boll et al.   NEUROCHEMICAL RESEARCH

Neuroprotective Effects of the Nonpsychoactive Cannabinoid Cannabidiol in Hypoxic-Ischemic Newborn Piglets

(2008) Francisco J Alvarez et al.   PEDIATRIC RESEARCH